Gallium(III) complexes of NOTA-bis (phosphonate) conjugates as PET radiotracers for bone imaging

Contrast Media and Molecular Imaging

Volumn 10, Issue 2, 2015, Pages 122-134

  Holub, Jan ^a   Meckel, Marian ^b   Kubíček, Vojtěch ^a   Rösch, Frank ^b   Hermann, Petr ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

68Ga radiopharmaceuticals; Bis(phosphonate); Bone targeting; in vivo imaging; Macrocyclic complexes; NOTA derivatives; Nuclear medicine; PET imaging; Phosphinate complexes; Radiotracer biodistribution

Indexed keywords

1,4,7 TRIAZACYCLONONE 1,4 DIACETIC ACID; ACETAMIDE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; GALLIUM 68; HYDROXYAPATITE; METHYLENEPHOSPHINATE; PHOSPHINE DERIVATIVE; TETRAXETAN; TRACER; UNCLASSIFIED DRUG; CONTRAST MEDIUM; GALLIUM;

ADSORPTION; ANIMAL EXPERIMENT; ARTICLE; BONE; COMPLEX FORMATION; CONJUGATION; DRUG DISTRIBUTION; HYDROLYSIS; ISOTOPE LABELING; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION; ANIMAL; CHEMISTRY; FEMUR; METABOLISM; PROCEDURES; RADIOGRAPHY;

ANIMALS; CONTRAST MEDIA; DIPHOSPHONATES; FEMUR; GALLIUM; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RATS;

EID: 84927557001     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.1606     Document Type: Article

References (53)

1. 68Ga radiopharmaceutical chemistry. Curr Top Med Chem 2010; 10: 1633-1668.
2. 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol Imag 2008; 3: 53-63.
3. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev 2010; 110: 2858-2902.
4. 68Ga]Ga-based imaging agents: chemistry and diversity. Med Chem 2011; 7: 345-372.
5. 68Ga-labeled radiopharmaceuticals for Positron Emission Tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med 2011; 41: 314-321.
6. Bartholomae MD. Recent developments in the design of bifunctional chelators for metal-based radiopharmaceuticals used in positron emission tomography. Inorg Chim Acta 2012; 389: 36-51.
7. Banerjee SR, Pomper MG. Clinical applications of gallium-68. Appl Radiat Isotop 2013; 76: 2-13.
8. Zhang S, Gangal G, Uludag H. Magic bullets' for bone diseases: progress in rational design of bone-seeking medicinal agents. Chem Soc Rev 2007; 36: 507-531.
9. Kubíček V, Lukeš I. Bone-seeking probes for optical and magnetic resonance imaging. Fut Med Chem 2010; 2: 521-531.
10. Palma E, Correia JDG, Campello MPC, Santos I. Bisphosphonates as radionuclide carriers for imaging or systemic therapy. Mol BioSyst 2011; 7: 2950-2966.
11. Fleisch H. Bisphosphonates in Bone Disease, 4th edn. Academic Press: London, 2000.
12. Kubíček V, Rudovský J, Kotek J, Hermann P, vander Elst L, Muller RN, Kolar ZI, Wolterbeek H T, Peters JA, Lukeš I. A bisphosphonate monoamide analogue of DOTA: a potential agent for bone targeting. J Am Chem Soc 2005; 127: 16477-16485.
13. Vitha T, Kubíček V, Hermann P, vander Elst L, Muller RN, Kolar ZI, Wolterbeek HT, Breeman WAP, Lukeš I, Peters JA. Lanthanide(III) complexes of bis(phosphonate) monoamide analogues of DOTA: bone-seeking agents for imaging and therapy. J Med Chem 2008; 51: 677-683.
14. Vitha T, Kubíček V, Kotek J, Hermann P, vander Elst L, Muller RN, Lukeš I, Peters JA. Gd(III) complex of a monophosphinate-bis(phosphonate) DOTA analogue with a high relaxivity. Lanthanide(III) complexes for imaging and radiotherapy of calcified tissues. Dalton Trans 2009; 3204-3214.
15. Liu W, Hajibeigi A, Lin M, Rostollan CL, Kovács Z, Öz OK, Sun X. An osteoclast-targeting agent for imaging and therapy of bone metastasis. Bioorg Med Chem Lett 2008; 18: 4789-4793.
16. 90Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases. Nucl Med Biol 2009; 36: 129-135.
17. 68Ga-chelate-conjugated bisphosphonate as a bone-seeking agent for PET imaging. Nucl Med Biol 2011; 38: 1011-1018.
18. 68Ga-bisphosphonates: first human study. Eur J Nucl Med Mol Imag 2010; 37: 834.
19. 68Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter. Nucl Med Biol 2012; 39: 993-996.
20. 68Ga labeled tracers and PET/CT to personalized radionuclide therapy - the Bad Berka experience. Theranostics 2012; 2: 437-447.
21. Vitha T, Kubíček V, Hermann P, Kolar ZI, Wolterbeek HT, Peters JA, Lukeš I. Complexes of DOTA-bisphosphonate conjugates: probes for determination of adsorption capacity and affinity constants of hydroxyapatite. Langmuir 2008; 24: 1952-1958.
22. 160Tb]terbium complexes of the bone-targeting ligands DOTP and BPPED. Langmuir 2009; 25: 2294-2301.
23. Heppeler A, Froidevaux S, Mäcke HR, Jermann E, Béhé M, Powell P, Hennig M. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J 1999; 5: 1974-1981.
24. Niu W, Wong EH, Weisman GR, Peng Y, Anderson CJ, Zakharov LN, Golen JA, Rheingold AL. Structural and dynamic studies of zinc, gallium, and cadmium complexes of a dicarboxylate pendant-armed cross-bridged cyclen. Eur J Inorg Chem 2004; 3310-3315.
25. Cola NA, Rarig, Jr. RS, Ouellette W, Doyle RP. Synthesis, structure and thermal analysis of the gallium complex of 1, 4, 7, 10-tetraazacyclododecane-N, N', N'', N'''-tetraacetic acid (DOTA). Polyhedron 2006; 25: 3457-3462.
26. Yang C-T, Li Y, Liu S. Synthesis and structural characterization of complexes of a DO3A-conjugated triphenylphosphonium cation with diagnostically important metal ions. Inorg Chem 2007; 46: 8988-8997.
27. Kubíček V, Havlíčková J, Kotek J, Tircsó G, Hermann P, Tóth É, Lukeš I. Gallium(III) complexes of DOTA and DOTA-monoamide: kinetic and thermodynamic studies. Inorg Chem 2010; 49: 10960-10969.
28. Šimeček J, Schulz M, Notni J, Plutnar J, Kubíček V, Havlíčková J, Hermann P. Complexation of metal ions with TRAP (1, 4, 7-triazacyclononane phosphinic acid) ligands and 1, 4, 7-triazacyclononane-1, 4, 7-triacetic acid: phosphinate-containing ligands as unique chelators for trivalent gallium. Inorg Chem 2012; 51: 577-590.
29. 68Ga tracers for positron emission tomography. Chem Eur J 2010; 16: 7174-7185.
30. Shetty D, Jeong JM, Ju CH, Kim YJ, Lee J-Y, Lee Y-S, Lee DS, Chung J-K, Lee MC. Synthesis and evaluation of macrocyclic amino acid derivatives for tumor imaging by gallium-68 positron emission tomography. Bioorg Med Chem 2010; 18: 7338-7347.
31. Shetty D, Choi SY, Jeong JM, Hoigebazar L, Lee Y-S, Lee DS, Chung J-K, Lee MC, Chung YK. Formation and characterization of gallium(III) complexes with monoamide derivatives of 1, 4, 7-triazacyclononane-1, 4, 7-triacetic acid: a study of the dependency of structure on reaction pH. Eur J Inorg Chem 2010; 5432-5438.
32. 68Ga-labeling and testing in tumor xenografted mice. J Med Chem 2010; 53: 6378-6385.
33. de Sá A, Matias ÁA, Prata MIM, Geraldes CFGC, Ferreira PMT, André JP. Gallium labeled NOTA-based conjugates for peptide receptor-mediated medical imaging. Bioorg Med Chem Lett 2010; 20: 7345-7348.
34. 68Ga-labelled bisphosphonates for bone imaging in non-tumour models. Nucl Med Biol 2013; 40: 823-830.
35. Blake AJ, Fallis IA, Gould RO, Persons S, Ross SA, Schröder M. Selective derivatisation of azamacrocycles. J Chem Soc Dalton Trans 1996; 4379-4387.
36. 1H NMR spectroscopy. J Am Chem Soc 1996; 118: 4396-4404.
37. Chong H-S, Song HA, Birch N, Le T, Lim S, Ma X. Efficient synthesis and evaluation of bimodal ligand NETA. Bioorg Med Chem Lett 2008; 18: 3436-3439.
38. 68Ga-radiolabelling and in vitro characterization of novel versatile bifunctional chelators for molecular imaging. Bioorg Med Chem Lett 2008; 18: 5364-5367.
39. 18F-labeling study. Chem Commun 2011; 47: 9732-9734.
40. Matczak-Jon E, Videnova-Adrabinska V. Supramolecular chemistry and complexation abilities of diphosphonic acids. Coord Chem Rev 2005; 249: 2458-2488.
41. Kubíček V, Kotek J, Hermann P, Lukeš I. Aminoalkyl-bis(phosphonates): their complexation properties in solution and in the solid state. Eur J Inorg Chem 2007; 333-344.
42. Broan C, Cox JP, Craig AS, Kataky R, Parker D, Harrison A, Randall AM, Ferguson G. Structure and solution stability of indium and gallium complexes of 1, 4, 7-triazacyclononanetriacetate and of yttrium complexes of 1, 4, 7, 10-tetraazacyclododecanetetraacetate and related ligands: kinetically stable complexes for use in imaging and radioimmunotherapy. X-Ray molecular structure of the indium and gallium complexes of 1, 4, 7-triazacyclononane-1, 4, 7-triacetic acid. J Chem Soc, Perkin Trans 2 1991; 87-99.
43. André JP, Mäcke HR, Zehnder M, Macko L, Akyel KG. 1, 4, 7-triazacyclononane-1-succinic acid-4, 7-diacetic acid (NODASA): a new bifunctional chelator for radio gallium-labelling of biomolecules. Chem Commun 1998; 1301-1302.
44. Lukeš I, Kotek J, Vojtíšek P, Hermann P. Complexes of tetraazacycles bearing methylphosphinic/phosphonic acid pendant arms with copper(II), zinc(II) and lanthanides(III). A comparison with their acetic acid analogues. Coord Chem Rev 2001; 216&217: 287-312.
45. Notni J, Šimeček J, Hermann P, Wester H-J. TRAP, a powerful and versatile framework for gallium-68 radiopharmaceuticals. Chem Eur J 2011; 17: 14718-14722.
46. Šimeček J, Notni J, Zemek O, Hermann P, Wester H-J. A monoreactive bifunctional triazacyclononane phosphinate chelator with high selectivity for gallium-68. ChemMedChem 2012; 7: 1375-1378.
47. 68Ga generator eluates? ChemMedChem 2013; 8: 95-103.
48. Notni J, Plutnar J, Wester H-J. Bone-seeking TRAP conjugates: surprising observations and their implications on the development of gallium-68-labeled bisphosphonates. EJNMMI Res 2012; 2: 13.
49. 2O. Inorg Chem 1982; 21: 4308-4314.
50. 3-. Inorg Chim Acta 1999; 290: 197-206.
51. Chang CA, Francesconi LC, Malley MF, Kumar K, Gougoutas JZ, Tweedle MF. Synthesis, characterization, and crystal structures of M(DO3A) (M=Fe, Gd) and Na[M(DOTA)] (M=Fe, Y, Gd). Inorg Chem 1993; 32: 3501-3508.
52. 68Ga for medical application. J Nucl Med 2007; 48: 1741-1748.
53. 68Ga for PET-imaging of bone metabolism. Radiochim Acta 2011; 99: 43-51.